Harbour BioMed has entered a strategic partnership with Otsuka focusing on the development of HBM7020 for treating autoimmune ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Dedicated datasets highlight how social determinants of health can be used to improve overall standards of care.

The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognize the people and companies that are ...